Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy

Obesity Surgery

Volumn 23, Issue 11, 2013, Pages 1790-1798

  Terra, Ximena ^a   Auguet, Teresa ^a,b   Guiu Jurado, Esther ^a   Berlanga, Alba ^a   Orellana Gavaldà, Josep Maria ^a   Hernández, Mercè ^c   Sabench, Fàtima ^c   Porras, Jose Antonio ^b   Llutart, Jordi ^b   Martinez, Salomé ^b   Aguilar, Carmen ^a   Del Castillo, Daniel ^c   Richart, Cristóbal ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Bariatric surgery; Body weight loss; Insulin resistance; Metabolic syndrome; Predictive model

Indexed keywords

ADIPOCYTOKINE; CHEMERIN; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; MORBID OBESITY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHEMOKINES; FASTING; FEMALE; GASTRECTOMY; GASTRIC BYPASS; GHRELIN; HUMANS; INSULIN RESISTANCE; LAPAROSCOPY; LEPTIN; MALE; OBESITY, MORBID; POSTOPERATIVE PERIOD; SPAIN; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84885477386     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-1033-9     Document Type: Article

References (34)

1. Gass M, Beglinger C, Peterli R. Metabolic surgery - principles and current concepts. Langenbecks Arch Surg. 2011;396(7):949-72.
2. Magee C, Barry J, Arumugasamy M, et al. Laparoscopic sleeve gastrectomy for high-risk patients: weight loss and comorbidity improvement - short-term results. Obes Surg. 2011;21(5):547-50.
3. Czupryniak L, Pawlowski M, Kumor A, et al. Predicting maximum Roux-en-Y gastric bypass-induced weight reduction - preoperative plasma leptin or body weight? Obes Surg. 2007;17(2):162-7.
4. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-71.
5. Beckman LM, Beckman TR, Sibley SD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. JPEN J Parenter Enteral Nutr. 2011;35(2):169-80.
6. Friedman JM. Obesity in the new millennium. Nature. 2000;404(6778):632-4.
7. Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest. 2010;40(3):277-80.
8. Chakaroun R, Raschpichler M, Klöting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metab Clin Exp. 2012;61(5):706-14.
9. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21(11):660-7.
10. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687-94.
11. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94(8):3085-8.
12. Kirchner H, Heppner KM, Tschöp MH. The role of ghrelin in the control of energy balance. Handb Exp Pharmacol. 2012;209:161-84.
13. Ortega E, Morínigo R, Flores L, et al. Predictive factors of excess body weight loss 1 year after laparoscopic bariatric surgery. Surg Endosc. 2012;26(6):1744-50.
14. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95.
15. Stefater MA, Wilson-Pérez HE, Chambers AP, et al. All bariatric surgeries are not created equal: Insights from mechanistic comparisons. Endocr Rev. 2012. doi: 10.1210/er.2011-1044.
16. Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One. 2012;7(4):e34710.
17. Shin H, Lee DC, Chu SH, et al. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol. 2011;77(1):47-50.
18. Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95(6):2892-6.
19. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87(1):240-4.
20. Gletsu LE. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg. 2004;139(7):780-4.
21. Peterli R, Steinert R, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740-8.
22. Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14(9):1208-15.
23. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88(4):1594-602.
24. Stratis C, Alexandrides T, Vagenas K, et al. Ghrelin and peptide YY levels after a variant of biliopancreatic diversion with Roux-en-Y gastric bypass versus after colectomy: a prospective comparative study. Obes Surg. 2006;16(6):752-8.
25. Delporte C. Recent advances in potential clinical application of ghrelin in obesity. J Obes. 2012. doi: 10.1155/2012/535624.
26. Oliván B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. World J Surg. 2011;35:2022-30.
27. Brethauer S, Heneghan H, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc. 2011;25:2650-9.
28. Felberbauer F, Langer F, Shakeri-Manesch S, et al. Laparoscopic sleeve gastrectomy as an isolated bariatric procedure: intermediate-term results from a large series in three Austrian centers. Obes Surg. 2008;18(7):814-8.
29. Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy - a prospective randomized trial. Surg Obes Relat Dis. 2011;7(5):561-8.
30. Franco JV, Ruiz PA, Palermo M, et al. A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding. Obes Surg. 2011;21(9):1458-68.
31. Woodard GA, Peraza J, Bravo S, et al. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20(5):578-82.
32. Benaiges D, Goday A, Ramon JM, et al. Laparoscopic sleeve gastrectomy and laparoscopic gastric bypass are equally effective for reduction of cardiovascular risk in severely obese patients at one year of follow-up. Surg Obes Relat Dis. 2011;7(5):575-80.
33. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring). 2006;14(9):1553-61.
34. Bado A, Levasseur S, Attoub S, et al. The stomach is a source of leptin. Nature. 1998;394(6695):790-3.